

Global TROP2 Antibody Market & Clinical Trials Insight 2026

<https://marketpublishers.com/r/GFF98B09EAD6EN.html>

Date: November 2021

Pages: 90

Price: US\$ 2,400.00 (Single User License)

ID: GFF98B09EAD6EN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global TROP2 Antibody Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights:

Research Methodology

Global & Regional Market Analysis

Global TROP2 Antibody Market Opportunity Assessment: > USD 4 Billion

Market and Drug Sales Insight 2020 Till 2026

Approved Drug In Market: 1 Drugs

Approved TROP2 Antibody Patent, Price and Sales insight 2020 Till 2026

Future Market Assessment By Indication Till 2026

Ongoing Clinical Trials Assessment by Status, Phase & Region

Key Market Dynamics

Competitor Landscape

Trophoblast surface antigen 2 (Trop2) is a cell surface protein which spans the epithelial membrane surface and plays role in cell self-renewal, proliferation, and transformation. Under normal physiological conditions, Trop2 has demonstrated its role in embryonic development, placental tissue formation, embryo implantation, stem cell proliferation, and organ development. Further, studies have also demonstrated that Trop2 is highly expressed on several cancer cells and is generally associated with its aggressive nature. Apart from this, it is also involved in several signaling pathways which ultimately lead to cancer cell growth and proliferation. Therefore, targeting Trop2 can be an alternative to target cancer.

Recently, scientists developed novel antibody drug conjugate in which the therapeutic antibody is targeted towards Trop2, thereby delivering the cytotoxin to the surface of tumor cell. Sacituzumab govitecan-hziy (Trodelvy) developed by Immunomedics is the first trop2 targeted antibody drug conjugate which has been approved for patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. The introduction of Trodelvy in 2020 is expected to witness high growth rates in market due to lack of effective targeted therapies in mTNBC. It is believed that Trodelvy will revolutionize the overall treatment of TNBC and will significantly improve the survival outcomes.

Beyond the approval of Trodelvy in US, it has also gained approval in Australia, Canada, UK, and Switzerland for adults with metastatic TNBC. Apart from this, the drug is present in regulatory view in other regions including Europe, China and Singapore. Recently, European Medicines Agency has recommended the marketing of Trodelvy, indicating that the drug will enter the market in coming months. The rapid approval of drug in different regions will fuel the growth of market in coming years.

The quick approval of Trodelvy has further empowered innovation and development in this sector. To date, a cocktail of Trop2 targeted drugs including DS-1062a, RN927C, BAT8003, SKB264, JS108 are present in clinical development. These drugs have been designed to target a wide range of cancer including non-small cell lung cancer, epithelial cancer, skin cancer, colon cancer, and others. Apart from this, several investigational studies are also ongoing to evaluate the efficacy of Trodelvy for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer and metastatic non-small cell lung cancer. Additional evaluation across multiple solid tumors is also underway. The forthcoming years will see rapid influx of Trop-2 targeted therapies in wide range of cancers.

The key players in the TROP2 Antibody market include Daiichi Sankyo, Immunomedics, Gilead Sciences, AstraZeneca, Pfizer, BioThera Solution, and others. The major players in the market have adopted strategic alliances such as collaboration, partnerships, or joint ventures to cope up with the high cost of research and development and to maintain their share in market. For instance, Daiichi Sankyo and AstraZeneca have recently announced second trial collaboration with Merck to evaluate the combination of datopotamab deruxtecan (Dato-DXd), a TROP2 directed DXd antibody drug conjugate (ADC) and Keytruda in non-small cell lung cancer patients.

The global Trop2 targeting drug market is expected to surpass US\$ 4 Billion by 2026. Surge in prevalence of cancer across geographies, high demand for targeted therapeutics for cancer treatment, favorable reimbursement policies offered by manufacturers and insurance providers, and rise in awareness of Trop-2 targeting drug owing to high efficiency will propel the growth of market. In addition, surge in geriatric population and increase in technological advancements in screening & diagnosis of cancer supplement the market growth.

Contents

1. INTRODUCTION TO TROP2 TARGETING THERAPY MARKET

- 1.1 Overview
- 1.2 History of TROP2 Targeting Therapeutics

2. TROP2 IDEAL CLINICAL BIOMARKER FOR CANCER

3. TROP2 TARGETING THERAPEUTICS MECHANISM

4. GLOBAL TROP2 TARGETING THERAPY MARKET ANALYSIS

- 4.1 Current Market Scenario
- 4.2 Future Market Opportunity

5. GLOBAL TROP2 TARGETING THERAPY MARKET OPPORTUNITY BY REGION

- 5.1 US
- 5.2 Europe
- 5.3 Japan
- 5.4 Rest of World

6. GLOBAL TROP2 TARGETING THERAPY MARKET BY CANCER

- 6.1 Breast Cancer
- 6.2 Urothelial Carcinoma
- 6.3 Lung Cancer
- 6.4 Pancreatic Cancer
- 6.5 Prostate Cancer

7. FIRST APPROVED TROP2 TARGETING ANTIBODY - TRODELVY (SACITUZUMAB GOVITECAN)

- 7.1 Overview
- 7.2 Approval, Patent & Exclusivity

8. TRODELVY - COMMERCIAL INFORMATION

8.1 Dosage & Price Analysis

8.2 Sales Analysis

9. TRODELVY SALES FORECAST 2026

10. TROP2 TARGETED THERAPY CLINICAL TRIALS INSIGHT

10.1 By Phase

10.2 By Development Status

10.3 By Region

11. GLOBAL TROP2 TARGETING THERAPY MARKET - ONGOING RESEARCH & DEVELOPMENT

11.1 Datopotamab Deruxtecan (DS-1062)

11.2 SKB264

11.3 JS108

11.4 BAT 8003

11.5 Trodelvy (Sacituzumab Govitecan)

12. GLOBAL TROP2 TARGETED THERAPY MARKET DYNAMICS

12.1 Market Drivers

12.2 Market Challenges

13. GLOBAL TROP2 TARGETING THERAPY MARKET FUTURE OUTLOOK

14. COMPETITIVE LANDSCAPE

14.1 Amunix

14.2 ARIUS Research

14.3 AstraZeneca

14.4 Biothera

14.5 Daiichi Sankyo Company

14.6 Gilead

14.7 Immunomedics

14.8 Janux Therapy

14.9 Klus Pharma

14.10 Myeloid therapeutics

14.11 Pfizer Inc

14.12 Shanghai Junshi Bioscience

List Of Figures

LIST OF FIGURES

Figure 1-1: Evolution of TROP2 Targeting Therapeutics

Figure 2-1: Frequency of TROP2 Expression by Cancer Type (%)

Figure 2-2: Role of TROP2 in Cancer

Figure 3-1: TROP2 Stimulated Effectors, Biomarker & Pathways

Figure 3-2: TROP2 Regulated Oncogenic Cell Signaling Pathways

Figure 3-3: General Mechanism of TROP2 Targeting Therapy

Figure 3-4: Trodelvy - Mechanism of Action

Figure 4-1: Global – Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 & 2030

Figure 4-2: Global – Number of Cancer Deaths (Million), 2020, 2025 & 2030

Figure 4-3: Global – TROP2 Targeting Therapy Market Opportunity (US\$ Million), 2020-2026

Figure 4-4: Global – Cancer Drug Market Opportunity (US\$ Billion), 2020-2026

Figure 4-5: Global – TROP2 Targeting Therapy Market by Product (%) 2026

Figure 5-1: US – Number of Newly Diagnosed Cancer Cases (Million), 2020-2026

Figure 5-2: US – TROP2 Targeting Therapy Market Opportunity (US\$ Million), 2020-2026

Figure 5-3: US – TROP2 Targeting Therapy Market by Product (%), 2026

Figure 5-4: Europe – Number of Newly Diagnosed Cancer Cases (Million), 2020-2026

Figure 5-5: Europe – TROP2 Targeting Therapy Market Opportunity (US\$ Million), 2022-2026

Figure 5-6: Europe – TROP2 Targeting Therapy Market by Product (%), 2026

Figure 5-7: UK – TROP2 Targeting Therapy Market Opportunity (US\$ Million), 2022 - 2026

Figure 5-8: Switzerland - TROP2 Targeting Therapy Market Opportunity (US\$ Million), 2022 - 2026

Figure 5-9: Japan – Number of Newly Diagnosed Cancer Cases (Million), 2020-2026

Figure 5-10: Japan – TROP2 Targeting Therapy Market Opportunity (US\$ Million), 2022-2026

Figure 5-11: Japan – TROP2 Targeting Therapy Market by Product (%), 2026

Figure 5-12: ROW – TROP2 Targeting Therapy Market Opportunity (US\$ Million), 2022-2026

Figure 5-13: ROW – TROP2 Targeting Therapy Market by Product (%), 2026

Figure 5-14: Canada - TROP2 Targeting Therapy Market Opportunity (US\$ Million), 2022 - 2026

Figure 5-15: Australia - TROP2 Targeting Therapy Market Opportunity (US\$ Million), 2022 - 2026

Figure 6-1: Global – Number of Newly Diagnosed Breast Cancer Cases (Million), 2021-2026

Figure 6-2: Global – Number of Newly Diagnosed Triple Negative Breast Cancer Cases, 2021-2026

Figure 6-3: Global – Breast Cancer TROP2 Targeting Therapy Market Opportunity (US\$ Million), 2021 - 2026

Figure 6-4: Global – Number of Urothelial Cancer Cases, 2021-2026

Figure 6-5: Global – Urothelial Cancer TROP2 Targeting Therapy Market Opportunity (US\$ Million), 2021-2026

Figure 6-6: Global – Number of Newly Diagnosed Lung Cancer Cases (Million), 2020-2026

Figure 6-7: Global –TROP2 Targeting Therapy Market Opportunity in Lung Cancer (US\$ Million), 2023 - 2026

Figure 6-8: Global – Number of Newly Diagnosed Pancreatic Cancer Cases, 2020-2026

Figure 6-9: Global – Number of Newly Diagnosed Prostate Cancer Cases (Million), 2020-2026

Figure 6-10: Global – Number of Newly Diagnosed Castration Positive Prostate Cancer Cases, 2020-2026

Figure 6-11: Global - Estimated Adoption Rates for TROP2 Targeting Therapy for Castration Positive Prostate Cancer, 2021-2026

Figure 7-1: Trodelvy – Response Rate in Clinical Study (%)

Figure 7-2: Trodelvy – FDA Approval Year Indication

Figure 7-3: Trodelvy – Patent Expiration Year by Region

Figure 7-4: Trodelvy – FDA Orphan Designation Year by Indication

Figure 8-1: Trodelvy – Average Cost of Single Dose Cycle & Single Treatment Cycle (US\$), September'2021

Figure 8-2: Global - Trodelvy Quarterly Sales Value (US\$ Million), Q2 – Q4' 2020

Figure 8-3: Global - Trodelvy Quarterly Sales Value (US\$ Million), Q1 – Q3' 2021

Figure 8-4: Trodelvy - US & Europe Sales Value (US\$ Million), Q3'2021

Figure 9-1: Global - Trodelvy Sales Forecast (US\$ Million), 2021 - 2026

Figure 9-2: US - Trodelvy Sales Forecast (US\$ Million), 2021 - 2026

Figure 9-3: Europe - Trodelvy Sales Forecast (US\$ Million), 2022 - 2026

Figure 9-4: Japan - Trodelvy Sales Forecast (US\$ Million), 2022 - 2026

Figure 9-5: ROW - Trodelvy Sales Forecast (US\$ Million), 2022 - 2026

Figure 9-6: UK - Trodelvy Sales Forecast (US\$ Million), 2022 - 2026

Figure 9-7: Switzerland - Trodelvy Sales Forecast (US\$ Million), 2022 - 2026

Figure 9-8: Canada - Trodelvy Sales Forecast (US\$ Million), 2022 - 2026

Figure 9-9: Australia - Trodelvy Sales Forecast (US\$ Million), 2022 - 2026

Figure 10-1: Global – Number of TROP2 Related Clinical Trials by Phase, September'2021

Figure 10-2: Global – TROP2 Related Clinical Trials by Phase (%), November'2021

Figure 10-3: Global – Number of TROP2 Related Clinical Trials by Development Status, November'2021

Figure 10-4: Global – Number of TROP2 Related Clinical Trials by Development Status (%), November'2021

Figure 10-5: Global – Number of TROP2 Related Clinical Trials by Region, November'2021

Figure 11-1: Investigational TROP2 Targeting Therapeutics

Figure 11-2: DS1062a Phase II Trial – NSCLC Study Initiation & Completion Year

Figure 11-3: DS1062a Phase II Trial – Metastatic NSCLC Study Initiation & Completion Year

Figure 11-4: DS1062a Phase III Trial – Comparative Study Initiation & Completion Year

Figure 11-5: DS1062a Phase I Trial – Study Initiation & Completion Year

Figure 11-6: DS1062a Phase I Combinational Trial – Metastatic NSCLC Study Initiation & Completion Year

Figure 11-7: SKB264 Phase I-II Trial – Study Initiation & Completion Year

Figure 11-8: JS108 Phase I Trial – Study Initiation & Completion Year

Figure 11-9: BAT8003 Phase I Trial – Study Initiation & Completion Year

Figure 11-10: IMMU132 Phase II Trial – Prostate Cancer Study Initiation & Completion Year

Figure 11-11: IMMU132 Phase II Trial – Endometrial Carcinoma Study Initiation & Completion Year

Figure 11-12: IMMU132 Phase II Trial – Metastatic Solid Tumors Study Initiation & Completion Year

Figure 11-13: IMMU132 Phase I-II Trial – Epithelial Cancer Study Initiation & Completion Year

Figure 11-14: IMMU132 Phase II Trial – Glioblastoma Study Initiation & Completion Year

Figure 12-1: Global TROP2 Targeting Therapy Market Drivers

Figure 12-2: Challenges for Global TROP2 Targeting Therapy Market

Figure 12-3: US – Annual Cost Comparison of TROP2 Targeting Therapy with other Treatments (US\$), November '2021

I would like to order

Product name: Global TROP2 Antibody Market & Clinical Trials Insight 2026

Product link: <https://marketpublishers.com/r/GFF98B09EAD6EN.html>

Price: US\$ 2,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GFF98B09EAD6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970